Sino Biopharmaceutical’s F-star Therapeutics Inks Third Licensing Deal with Takeda for Immunotherapies
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a third licensing agreement between its subsidiary, F-star...
F-star Therapeutics
Sino Biopharmaceutical’s Subsidiary invoX Completes Additional Investment in pHion Therapeutics
The UK-based invoX Pharma Ltd, a wholly-owned subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177),...
Sino Biopharmaceutical’s F-star Therapeutics Signs Second Licensing Deal with Takeda
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a second licensing agreement between its recently acquired...
F-star Therapeutics’ Acquisition by invoX Pharma Cleared by CFIUS
UK biotech F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that it has received clearance from...
F-Star Therapeutics and Sino Biopharmaceutical Seek CFIUS Approval with Extended Deadline
The acquisition of UK-based biologics firm F-Star Therapeutics (NASDAQ: FSTX) by China’s Sino Biopharmaceutical (HKG:...
F-star Therapeutics and Sino Biopharmaceutical Face Delays in Proposed Acquisition
UK-based biotech F-star Therapeutics (NASDAQ: FSTX) released an SEC filing indicating that the proposed acquisition...
F-Star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Again
UK-based F-Star Therapeutics Inc., (NASDAQ: FSTX) revealed that there has been yet another delay to...
F-star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Amid CFIUS Review
UK-based biotech F-star Therapeutics Inc. (NASDAQ: FSTX) announced in a stock exchange press release that...
invoX Pharma Extends Tender Offer for F-star Therapeutics to September 19
invoX Pharma Ltd, a UK-based subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177), announced that...